Literature DB >> 21217487

Improved survival after hemostatic resuscitation: does the emperor have no clothes?

Louis J Magnotti1, Ben L Zarzaur, Peter E Fischer, Regan F Williams, Adrianne L Myers, Eric H Bradburn, Timothy C Fabian, Martin A Croce.   

Abstract

BACKGROUND: In light of recent data, controversy surrounds the apparent 30-day survival benefit of patients achieving a fresh frozen plasma (FFP) to packed red blood cell (PRBC) ratio of at least 1:2 in the face of massive transfusions (MT) (≥10 units of PRBC within 24 hours of admission). We hypothesized that initial studies suffer from survival bias because they do not consider early deaths secondary to uncontrolled exsanguinating hemorrhage. To help resolve this controversy, we evaluated the temporal relationship between blood product administration and mortality in civilian trauma patients receiving MT.
METHODS: Patients requiring MT over a 22-month period were identified from the resuscitation registry of a Level I trauma center. Shock severity at admission and timing of shock-trauma admission, blood product administration, and death were determined. Patients were divided into high- and low-ratio groups (≥1:2 and<1:2 FFP:PRBC, respectively) and compared. Kaplan-Meier analysis and log-rank test was used to examine 24-hour survival.
RESULTS: One hundred three patients (63% blunt) were identified (66 high-ratio and 37 low-ratio). Those patients who achieved a high-ratio in 24 hours had improved survival. However, severity of shock was less in the high-group (base excess: -8.0 vs. -11.2, p=0.028; lactate: 6.3 vs. 8.4, p=0.03). Seventy-five patients received MT within 6 hours. Of these, 29 received a high-ratio in 6 hours. Again, severity of shock was less in the high-ratio group (base excess: -7.6 vs. -12.7, p=0.008; lactate: 6.7 vs. 9.4, p=0.02). For these patients, 6-hour mortality was less in the high-group (10% vs. 48%, p<0.002). After accounting for early deaths, groups were similar from 6 hours to 24 hours.
CONCLUSIONS: Improved survival was observed in patients receiving a higher plasma ratio over the first 24 hours. However, temporal analysis of mortality using shorter time periods revealed those who achieve early high-ratio are in less shock and less likely to die early from uncontrolled hemorrhage compared with those who never achieve a high-ratio. Thus, the proposed survival advantage of a high-ratio may be because of selection of those not likely to die in the first place; that is, patients die with a low-ratio not because of a low-ratio.

Entities:  

Mesh:

Year:  2011        PMID: 21217487     DOI: 10.1097/TA.0b013e3182051691

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  19 in total

1.  The impact of increased plasma ratios in massively transfused trauma patients: a prospective analysis.

Authors:  E Bui; K Inaba; A Ebadat; E Karamanos; S Byerly; O Okoye; I Shulman; P Rhee; D Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2015-09-11       Impact factor: 3.693

2.  Resveratrol Improves Survival and Prolongs Life Following Hemorrhagic Shock.

Authors:  Ahmar Ayub; Ninu Poulose; Raghavan Raju
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

Review 3.  Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography.

Authors:  Eduardo Gonzalez; Fredric M Pieracci; Ernest E Moore; Jeffry L Kashuk
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

Review 4.  Coagulopathy after severe pediatric trauma.

Authors:  Sarah C Christiaans; Amy L Duhachek-Stapelman; Robert T Russell; Steven J Lisco; Jeffrey D Kerby; Jean-François Pittet
Journal:  Shock       Date:  2014-06       Impact factor: 3.454

Review 5.  The pathophysiology, diagnosis and treatment of the acute coagulopathy of trauma and shock: a literature review.

Authors:  J Kaczynski; M Wilczynska; L Fligelstone; J Hilton
Journal:  Eur J Trauma Emerg Surg       Date:  2013-12-12       Impact factor: 3.693

6.  Implementation of a military-derived damage-control resuscitation strategy in a civilian trauma center decreases acute hypoxia in massively transfused patients.

Authors:  Eric M Campion; Timothy A Pritts; Warren C Dorlac; Anjelica Q Nguyen; Sara M Fraley; Dennis Hanseman; Bryce R H Robinson
Journal:  J Trauma Acute Care Surg       Date:  2013-08       Impact factor: 3.313

7.  [Efficacy of high versus low plasma: red blood cell ratio resuscitation in patients with severe trauma requiring massive blood transfusion: a meta-analysis].

Authors:  Fang Yu; Tao Zhong; Gang Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

8.  Early resuscitation intensity as a surrogate for bleeding severity and early mortality in the PROMMTT study.

Authors:  Elaheh Rahbar; Erin E Fox; Deborah J del Junco; John A Harvin; John B Holcomb; Charles E Wade; Martin A Schreiber; Mohammad H Rahbar; Eileen M Bulger; Herb A Phelan; Karen J Brasel; Louis H Alarcon; John G Myers; Mitchell J Cohen; Peter Muskat; Bryan A Cotton
Journal:  J Trauma Acute Care Surg       Date:  2013-07       Impact factor: 3.313

Review 9.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

10.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.